€1.25
Your prediction
Marinus Pharmaceuticals Inc. Stock
Pros and Cons of Marinus Pharmaceuticals Inc. in the next few years
Pros
Cons
News
Marinus Pharmaceuticals Announces Key Business Updates for Tuberous Sclerosis Complex Program
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced completion of enrollment in
Marinus Pharmaceuticals Provides Business Update and Reports First Quarter 2024 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today reported business highlights and
Marinus Pharmaceuticals to Present at the RBC Capital Markets 2024 Global Healthcare Conference
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders, today announced that Scott Braunstein